



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	65617US(54086)
-------	---	----	---	------------------------	----------------

Complete If Known

Application Number	10/580,098
Filing Date	May 19, 2006
First Named Inventor	Adam McCluskey
Art Unit	N/A
Examiner Name	Not Yet Assigned Walter Webb

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CA		Wikipedia information on Curcumin: < http://en.wikipedia.org/wiki/Curcumin >	
CB		Ohmichi, M., Pang, L., Ribon, V., Gazit, A., Levitzki, A. and Saliel, A.R. (1993) The tyrosine kinase inhibitor tryphostin blocks the cellular actions of nerve growth factor. <i>Biochemistry</i> 32 : 4650-4658.	
CC		Gazit, A., Oshero, N., Posner, I., Yaish, P., Poradosu, E., Gilon, C. and Levitzki, A. (1991) Typhostins. Heterocyclic and α -substituted benzylidenemalononitrile typhostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. <i>J. Med. Chem.</i> 34 : 1896-1907.	
CD		Mazumder, A., Gazit, A., Levitzki, A., Nicklaus, M., Yung, J., Kohlhagen, G. and Pommier, Y. (1995) Effects of typhostins, protein kinase inhibitors, on human immunodeficiency virus type I integrase. <i>Biochemistry</i> 34 : 15111-15122.	
CE		Gazit, A., App, H., McMahon, G., Chen, J., Levitzki, A. and Bohmer, F.D. (1998) Typhostins. 5. Potent inhibitor of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole typhostins. <i>J. Med. Chem.</i> 39 : 2170-2177.	
CF		Gazit, A., Oshero, N., Gilon, C. and Levitzki, A. (1996) Typhostins. 6. Dimeric benzylidenemalononitrile typhostins: potent inhibitors of EGF receptor tyrosine kinase <i>in vitro</i> . <i>J. Med. Chem.</i> 39 : 4905-4911.	
CG		Levitzki, A., Gazit, A., Oshero, N., Posner, I. and Gilon, C. (1991) Inhibition of protein-tyrosine kinases by typhostins. <i>Methods in Enzymology</i> 201 : 347-361.	
CH		Posner, I., Engel, M., Gazit, A. and Levitzki, A. (1993) Kinetics of inhibition by typhostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. <i>Molecular Pharmacology</i> 45 : 673-683.	
CI		Levitzki, A. and Gilon, C. (1991) Typhostins as molecular tools and potential antiproliferative drugs. <i>Trends in Pharmacological Sciences</i> 12 : 171-174.	
CJ		Wijetunge, S. and Hughes, A.D. (1995) Effect of platelet-derived growth factor on voltage-operated calcium channels in rabbit isolated ear artery cells. <i>Br. J. Pharmacol.</i> 115 : 534-538 (ABSTRACT).	
CK		Wijetunge, S., Lynn, J.S. and Hughes, A.D. (2000) Effects of protein tyrosine kinase inhibitors on voltage-operated calcium channel currents in vascular smooth muscle cells and pp60 ^{c-src} kinase activity. <i>British Journal of Pharmacology</i> 129 : 1347-1354.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Walter Webb/	Date Considered	05/20/2008
--------------------	---------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.W./